AADI - Aadi Bioscience, Inc.
IEX Last Trade
3.19
0.155 4.859%
Share volume: 951
Last Updated: Thu 02 Jan 2025 08:30:14 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.18%
PREVIOUS CLOSE
CHG
CHG%
$3.04
0.16
5.11%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-1.71%
1 Month
33.69%
3 Months
60.97%
6 Months
122.18%
1 Year
56.19%
2 Year
-75.41%
Key data
Stock price
$3.19
DAY RANGE
$3.04 - $3.16
52 WEEK RANGE
$1.41 - $3.60
52 WEEK CHANGE
$61.79
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Neil P. Desai
Region: US
Website: aadibio.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: aadibio.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin.
Recent news